EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Theranostics in the management of prostate cancer: from concept to clinical practice

Kannan Sridharan iD, Teresa Alonso-Gordoa, Gowri Sivaramakrishnan, Javier Molina Cerrillo, Ondrej Fiala, Farah Rehan, Danny Mena Cortes, Matteo Santoni

Expert Review of Clinical Pharmacology · 2026

DOI: 10.1080/17512433.2026.2737765 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2026. Verfasst von Kannan Sridharan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama, Bahrain. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiopharmaceuticals. Die Arbeit nennt 136 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Radiotheranostics, integrating diagnostic imaging with targeted radiotherapy using molecularly matched radioactive agents, has emerged as a transformative approach in the management of prostate cancer. Prostate-specific membrane antigen (PSMA) is the dominant clinically validated target, and PSMA-targeted radioligand therapy has rapidly reshaped the treatment landscape across disease states. AREAS COVERED: This is a comprehensive overview of the prostate cancer theranostics landscape, with a primary focus on PSMA. We synthesized evidence from landmark randomized trials, guideline documents, and emerging data on alpha-emitting agents, combination strategies, and next-generation constructs. Literature search encompassed pivotal phase II/III trials, guideline documents, and contemporary mechanistic studies. Patient selection, distinguishing clinical-trial eligibility, regulatory indications, and guideline recommendations, is critically appraised. EXPERT OPINION: PSMA-targeted radioligand therapy has fundamentally reshaped the treatment paradigm, with [177Lu]Lu-PSMA-617 established in PSMA-positive metastatic castration-resistant prostate cancer and now expanding into earlier disease states, including metastatic hormone-sensitive prostate cancer. The future lies in biomarker refinement, rational combinations with poly(ADP-ribose) polymerase inhibitors, androgen receptor pathway inhibitors, and immunotherapy, and next-generation platforms including alpha-emitters and bispecific agents. Multidisciplinary integration and structured monitoring will be essential for optimizing outcomes as theranostics becomes a sequence-defining therapeutic platform.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsRadiopharmaceuticalsHumansMaleMolecular Targeted TherapyAntigens, SurfaceGlutamate Carboxypeptidase IIPatient SelectionAnimalsRandomized Controlled Trials as TopicProstatic Neoplasms, Castration-ResistantDipeptidesHeterocyclic Compounds, 1-RingGlycopeptidesBiomarkers, TumorLutetiumRadioisotopesProstate-Specific Antigen

Stichwörter der Autor:innen

PSMA-targeted radioligand therapyTheranostics[177Lu] Lu-PSMA-617castration-resistant prostate cancermolecular imaging

Substanzen

RadiopharmaceuticalsAntigens, SurfaceGlutamate Carboxypeptidase IIFOLH1 protein, humanDipeptidesHeterocyclic Compounds, 1-RingGlycopeptidesBiomarkers, TumorPSMA-617Lutetium

Autor:innen und Institutionen

  • Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama, Bahrain.
  • Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Bahrain Defence Force Royal Medical Services, Riffa, Bahrain.
  • ARON Research Foundation ETS, Macerata, Italy.
  • Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital Pilsen, Charles University, Pilsen, Czechia.
  • Biomedical Center, Faculty of Medicine, Charles University, Pilsen, Czechia.

ORCID-Profile: Kannan Sridharan

Zitieren

APA

Sridharan, K., Alonso-Gordoa, T., Sivaramakrishnan, G., Cerrillo, J. M., Fiala, O., Rehan, F., Mena Cortes, D., & Santoni, M. (2026). Theranostics in the management of prostate cancer: from concept to clinical practice. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2026.2737765

Vancouver

Sridharan K, Alonso-Gordoa T, Sivaramakrishnan G, Cerrillo JM, Fiala O, Rehan F, et al. Theranostics in the management of prostate cancer: from concept to clinical practice. Expert Review of Clinical Pharmacology. 2026. doi:10.1080/17512433.2026.2737765

BibTeX
@article{Sridharan2026,
  author = {Sridharan, Kannan and Alonso-Gordoa, Teresa and Sivaramakrishnan, Gowri and Cerrillo, Javier Molina and Fiala, Ondrej and Rehan, Farah and Mena Cortes, Danny and Santoni, Matteo},
  title = {Theranostics in the management of prostate cancer: from concept to clinical practice},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2026},
  doi = {10.1080/17512433.2026.2737765}
}
Kostenlos starten →